Paraneoplastic cerebellar degeneration as initial presentation of a pancreatic small-cell carcinoma;Degeneración cerebelosa paraneoplásica como inicio de un carcinoma indiferenciado de células pequeñas de páncreas

Revista de Neurologia

Volumn 35, Issue 12, 2002, Pages 1112-1115

  Salmeron Ato P ^a   Medrano, V ^b   Morales Ortiz, A ^c   Martinez Garcia F ^d   Villaverde Gonzalez R ^d   Bas, A ^d   Fernandez Barreiro A ^d   Molto Jorda J M ^e  

^a HOSPITAL RAFAEL MÉNDEZ   (Spain)

^b Hospital Comarcal de Elda   (Spain)

^c Hospital Sta María del Rosell   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Carcinoma small cell; Encephalomyelitis therapy; Pancreatic malignancies; Paraneoplastic cerebellar degeneration; Paraneoplastic syndromes

Indexed keywords

ANTIBODY; HU ANTIBODY; UNCLASSIFIED DRUG; YO ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; BRAIN DISEASE; BREAST CARCINOMA; CASE REPORT; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; ENCEPHALITIS; HUMAN; MALE; NEUROBLASTOMA; NEUROPATHY; OAT CELL CARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREATIC SMALL CELL CARCINOMA; PARANEOPLASTIC NEUROPATHY; PROSTATE CARCINOMA; SARCOMA; SEMINOMA;

EID: 0037122401     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3512.2002562     Document Type: Article

References (38)

1. Dalmau J, Graus F. Paraneoplastic syndromes. In Samuels MA, ed. Office practice of Neurology. New York: Churchill-Livingstone; 1996. p. 925-34.
2. Kotanides H, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration. II. Clinical and immunological findings in 21 patients with Hodgkin's disease. Neurology 1992; 42: 1938-43.
3. Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120: 1279-300.
4. Peterson K, Tosemblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42: 1931-7.
5. Ferrer I. Patología de los sindromes paraneoplásicos del sistema nervioso central, periférico y músculo. Rev Neurol 2000; 31: 1228-36.
6. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine 1992; 71: 59-72.
7. Bechich S, Graus F. El diagnóstico actual de los síndromes paraneo-plásicos. Continua Neurológica 2000; 3: 16-26.
8. Fisher PG, Wechsler DS, Singer HS. Anti-Hu antibody in a neuroblastoma-associated paraneoplastic syndrome. Pediatr Neurol 1994; 10: 309-12.
9. Verschuuren J, Twijnstra A, De Baets M, Thunnissen F, Dalmau J, Van Breda-Vriesman P. Hu antigens and anti-Hu antibodies in a patient with myxoid chondrosarcoma. Neurology 1994; 44: 1551-2.
10. Reyes CV, Wang T. Undifferentiated small cell carcinoma of the pancreas. Cancer 1981; 41: 2500-2.
11. Hobbs RD, Stewart AF, Ravin ND, Carter D. Hypercalcemia in small cell carcinoma of the pancreas. Cancer 1984; 53: 1552-4.
12. Darnell RB. Onconeural antigens and paraneoplastic neurologic disorders: at the intersection of cancer, immunity and the brain. Proc Natl Acad Sci USA 1996; 93: 4529-36.
13. Lang B, Vincent A. Autoimmunity to ion channels and other proteins in paraneoplastic disorders. Curr Opin Immunol 1996; 8: 865-87.
14. Voltz R, Dalmau J, Posner JB, Rosenfeld MR. T-cell receptor analysis in anti-Hu-associated paraneoplastic encephalomyelitis. Neurology 1998; 51: 1146-50.
15. Graus F, Cordón-Cardó C, Posner BP. Neuronal antinuclear antibody in sensory neuropathy from lung cancer. Neurology 1985; 35: 538-43.
16. Manley GT, Smitt PS, Dalmau J, Posner JB. Hu antigens: reactivity with Hu antibodies, tumour expression, and major immunogenic sites. Ann Neurol 1995; 38: 102-10.
17. Dalmau J, Porta-Etessam J. Síndromes paraneoplásicos cerebrales con manifestación otoneuroftalmológica. Rev Neurol 2000; 31: 1213-9.
18. Marés-Segura R. Síndromes paraneoplásicos medulares. Rev Neurol 2000; 31: 1219-23.
19. Graus F, Reñe R. Paraneoplastic neuropathies. Eur Neurol 1993; 33: 279-86.
20. Graus F, Bonaventura I, Uchuya M, Valls-Solé J, Reñe R, Leger JM, et al. Indolent anti-Hu-associated paraneoplastic sensory neuronopathy. Neurology 1994; 44: 2258-61.
21. Lucchinetti CF, Kimmel DW, Lenoon VA. Paraneoplastic and oncologic profiles of seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50: 652-7.
22. Posner JB. Paraneoplastic syndromes involving the nervous system. In Aminoff MJ, ed. Neurology and general medicine. New York: Churchill-Livingstone; 1989. p. 341-64.
23. th Annual Meeting, Boston.
24. Graus F, Vega F, Delattre JY, Bonaventura I, Reñé R, Arbaiza D, et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal antibodies. Neurology 1992; 42: 536-40.
25. Uchuya M, Graus F, Vega F, Reñé R, Delattre JY. Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes with antineuronal antibodies. J Neurol Neurosurg Psychiatry 1996; 60: 388-92.
26. Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Eaton-Lambert myasthenic syndrome. Brain 1997; 120: 1279-300.
27. Mason WP, Dalmau J, Curtin JP, Posner JB. Normalization of the tumour marker CA-125 after oophorectomy in a patient with paraneoplastic cerebellar degeneration without detectable cancer. Gynecol Oncol 1997; 65: 173-6.
28. Paone JF, Jeyasingham K. Remission of cerebellar dysfunction after pneumonectomy for bronchogenic carcinoma. N Engl J Med 1980; 302: 156.
29. Cocconi G, Ceci G, Juvarra G. Successful treatment of subacute cerebellar degeneration in ovarian carcinoma with plasmapheresis. A case report. Cancer 1985; 56: 2318-20.
30. Batson OA, Gantle DM, Stewart JA. Paraneoplastic encephalomyelitis. Dramatic response to cheotherapy alone. Cancer 1992; 69: 1291-3.
31. Counssell CE, McLeod M, Grant R. Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology 1994; 44: 1184-5.
32. Cher LM, Hochberg FH, Teruya J, Nitschke M, Valenzuela RF, Schmahmann JD, et al. Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoabsortion. Cancer 1995; 75: 1678-83.
33. Stark E, Wurster-Upatzold U, Sailer M, Haas J. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol 1995; 52: 814-8.
34. David YB, Warner E, Levitan M, Sutton DM, Malkin MG, Dalmau J. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer 1996; 78: 2153-6.
35. Rojas-Marcos I, Reñé R, Graus F. Síndromes paraneoplásicos en otoneuroftalmología. Rev Neurol 2000; 31: 1206-12.
36. Keime-Guibert HF, Graus F, Bröet P, Reñé R, Molinuevo JL, Ascaso C, et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumour. Neurology 1999; 53: 1719-23.
37. Gridold W, Drlicek M, Liszka-Setinek U, Wondrusch EA. Anti-tumour therapy in paraneoplastic neurological disease. Clin Neurol Neurosurg 1995; 97: 106-111.
38. Chabriat H, Chen QM, Poisson M, Delatre JY. Degenerescence cérébelleuse paranéoplasique. Rev Neurol (Paris) 1994; 150: 105-14.